Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
IQVIA Holdings
Create a narrative
IQVIA Holdings Community
NYSE:IQV Community
3
Narratives
written by author
0
Comments
on narratives written by author
28
Fair Values set
on narratives written by author
Community Investing Ideas
IQVIA Holdings
Popular
Undervalued
Overvalued
IQVIA Holdings
AN
AnalystHighTarget
Consensus Narrative from 19 Analysts
NVIDIA Partnership And AI Deployment Will Fuel Healthcare Digitization
Key Takeaways IQVIA's leadership in real-world data analytics and generative AI is driving faster revenue growth, margin expansion, and operational efficiency beyond market expectations. Strategic expansion in global data assets and emerging markets positions IQVIA for strong, resilient growth, recurring revenue, and increasing market share as healthcare digitizes.
View narrative
US$255.83
FV
25.4% undervalued
intrinsic discount
6.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
5 days ago
author updated this narrative
IQVIA Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Key Takeaways Accelerated AI adoption and proprietary platforms, alongside strategic partnerships, strengthen IQVIA's operational efficiency, market differentiation, and create significant competitive barriers. Sustained growth in real-world evidence and clinical research demand boosts project backlog and revenue visibility, supporting long-term expansion and earnings resilience.
View narrative
US$215.05
FV
11.3% undervalued
intrinsic discount
5.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
5 days ago
author updated this narrative
IQVIA Holdings
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Rising Regulatory Burdens And High Debt Will Limit Operations
Key Takeaways Tighter data privacy laws and public scrutiny may restrict growth in analytics platforms and reduce client spending on clinical research services. Rising competition, heavy reliance on debt, and industry consolidation threaten contract wins, financial flexibility, and long-term earnings expansion.
View narrative
US$168.00
FV
13.6% overvalued
intrinsic discount
4.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
17 days ago
author updated this narrative
Your Valuation for
IQV
IQV
IQVIA Holdings
Your Fair Value
US$
Current Price
US$190.81
17.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
20b
2015
2018
2021
2024
2025
2027
2030
Revenue US$20.3b
Earnings US$1.6b
Advanced
Set Fair Value